



UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium)

Press Release

Two Senior Pharma Executives as New Members of UCB's Executive Committee

Brussels, November 22, 2005 - UCB announced the appointment of Bill Robinson, Executive Vice President, Global Operations and Bob Trainor, Executive Vice President, General Counsel, as new members of UCB's Executive Committee.

Bill Robinson is British and has built an impressive international career with Eli Lilly and Company retiring in 2004 as Vice President, Operational Excellence, Pharmaceutical Operations and prior to this, as Vice President, heading the U.S. Sales and Marketing activities (primary care and neuroscience). Bill also held a number of general management, marketing and clinical development roles in the USA, Europe, Asia and Africa during his 30+ year career with Eli Lilly.

Bob Trainor is American and has gained significant experience and expertise in international corporate law within the pharmaceutical industry. Bob held senior positions at Schering-Plough (1992-2004) as Vice President Associate General Counsel and member of the Operations Management Committee, as well as at Johnson & Johnson (1982-1992) as Assistant General Counsel. Prior to joining the pharmaceutical industry, Bob developed his legal skills with the New York-based law firm Donovan Leisure Newton & Irvine and with the United States House of Representatives - Committee on the Judiciary.

UCB's Executive Committee comprises also Melanie Lee, Executive Vice President R&D, Luc Missorten, Executive Vice President Chief Financial Officer, Jean-Pierre Pradier, Executive Vice President Corporate Human Resources, and is chaired by Roch Doliveux, Chief Executive Officer.

About UCB

UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, inflammatory diseases, and oncology. UCB key products are Keppra[®] (antiepileptic), Xyzal[®] and Zyrtec[®] (antiallergics), Nootropil[®] (cerebral function regulator), Tussionex[™] (antitussive) and Metadate[™] / Equasym XL[™] (attention deficit/hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries. UCB is listed on Euronext Brussels (UCB / UCBBt.BR / UCB BB).

For further information please contact:

Jean-Christophe Donck

Vice President

Corporate Communication & Investor Relations

Phone +32 2 559 9588

Fax +32 2 559 9571

Email jc.donck@ucb-group.com